The possible benefit from total tumour resection in primary diffuse large B-cell lymphoma of central nervous system – a one-decade single-centre experience

References

• Ghesquières H, Drouet Y, Sunyach MP, et al. Evidence of time-dependent prognostic factors predicting early death but not long-term outcome in primary CNS lymphoma: a study of 91 patients. Hematol Oncol 2013;31:57–64.
   PubMed Web of Science ®Google Scholar
• Kellogg RG, Straus DC, Karmali R, Munoz LF, Byrne RW. Impact of therapeutic regimen and clinical presentation on overall survival in CNS lymphoma. Acta Neurochir 2014;156:355–65.
   PubMed Web of Science ®Google Scholar
• De Angelis LM. Primary central nervous system lymphoma: Coming or going? Blood 2009;113:4483–4.
   PubMed Web of Science ®Google Scholar
• Ponzoni M, Issa S, Batchelor T, Rubenstein JL. Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma. Ann Oncol 2014;25:316–22.
   PubMed Web of Science ®Google Scholar
• Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: The next step. J Clin Oncol 2000;18:3144–50.
   PubMed Web of Science ®Google Scholar
• Sung CO, Kim SC, Karnan S, et al. Genomic profiling combined with gene expression profiling in primary central nervous system lymphoma. Blood 2011;117:1291–300.
   PubMed Web of Science ®Google Scholar
• Bhagavathi S, Sharathkumar A, Hunter S, et al. Activated B-cell immunophenotype might be associated with poor prognosis of primary central nervous system lymphomas. Clin Neuropathol 2008;27:13–20.
   PubMed Web of Science ®Google Scholar
• Tun HW, Personett D, Baskerville KA, et al. Pathway analysis of primary central nervous system lymphoma. Blood 2008;111: 3200–10.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275–82.
   PubMed Web of Science ®Google Scholar
• A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987–94.
   Google Scholar
• Ferreri AJ, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 2003;21:266–72.
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Gupta NK, Mannis GN, et al. How I treat CNS lymphomas. Blood 2013;122:2318–30.
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Marturano E. Primary CNS lymphoma. Best Pract Res Clin Haematol 2012;25:119–30.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol 1999;17:1244–53.
   PubMed Web of Science ®Google Scholar
• Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer 2011;105:1414–18.
   PubMed Web of Science ®Google Scholar
• Shenkier TN, Blay JY, O’Neill BP, et al. Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. J Clin Oncol 2005;23:2233–9.
   PubMed Web of Science ®Google Scholar
• Camilleri-Broet S, Criniere E, Broet P, et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood 2006;107:190–6.
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Reni M, Pasini F, et al. A multicenter study of treatment of primary CNS lymphoma. Neurology 2002;58:1513–20.
   PubMed Web of Science ®Google Scholar
• Bokstein F, Lossos A, Lossos IS, Siegal T. Central nervous system relapse of systemic non-Hodgkin's lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy. Leuk Lymphoma 2002;43:587–93.
   PubMed Web of Science ®Google Scholar
• DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ; Radiation Therapy Oncology Group Study 93-10. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93–10. J Clin Oncol 2002;20:4643–8.
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 2009;374:1512–20.
   PubMed Web of Science ®Google Scholar
• DeAngelis LM. Whither whole brain radiotherapy for primary CNS lymphoma? Neuro Oncol 2014;16:103–4.
   PubMed Web of Science ®Google Scholar
• Deangelis LM, Iwamoto FM. An update on therapy of primary central nervous system lymphoma. Hematology Am Soc Hematol Educ Program 2006;311–16.
   PubMedGoogle Scholar
• Weller M, Martus P, Roth P, Thiel E, Korfel A; German PCNSL Study Group. German PCNSL Study Group. Surgery for primary CNS lymphoma? Challenging a paradigm. Neuro Oncol 2012;14:1481–4.
   PubMed Web of Science ®Google Scholar
• Abrey LE, Moskowitz CH, Mason WP, et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 2003;21:4151–6.
   PubMed Web of Science ®Google Scholar
• Schorb E, Kasenda B, Atta J, et al. Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation. Haematologica 2013;98:765–70.
   PubMed Web of Science ®Google Scholar